Roche licenses, co-promotes Chugai's RA drug
Executive Summary
Roche's F. Hoffmann-La Roche has licensed exclusive rights to Chugai Pharmaceutical's rheumatoid arthritis drug MRA (atlizumab). Roche will have intellectual property and trademark rights worldwide except in Japan, South Korea, and Taiwan, territories that Chugai will retain.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice